Focusing downstream in lung cancer prevention: 15-hydroxyprostaglandin dehydrogenase

Cancer Prevention Research

Volumn 1, Issue 4, 2008, Pages 223-225

  Dubinett, Steven M ^a   Mao, Jenny T ^a   Hazra, Saswati ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CYCLOOXYGENASE 2; PTGS2 PROTEIN, HUMAN;

CHEMOPROPHYLAXIS; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METHODOLOGY; NOTE; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMOPREVENTION; CYCLOOXYGENASE 2; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; LUNG NEOPLASMS; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

EID: 61549141756     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0148     Document Type: Review

References (44)

1. Sevenoaks MJ, Stockley RA. Chronic obstructive pulmonary disease, inflammation and co-morbidity -a common inflammatory phenotype? Respir Res 2006;7:70.
2. Lee JM, Yanagawa J, Peebles KA, et al. Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol 2008;66:208-17.
3. Katori M, Majima M. Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors. Inflamm Res 2000;49:367-92.
4. FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003;2:879-90.
5. Malkowski MG, Ginell SL, Smith WL, et al. The productive conformation of arachidonic acid bound to prostaglandin synthase. Science 2000;289: 1933-7.
6. Huang M, Stolina M, Sharma S, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998;58:1208-16.
7. Subbaramaiah K, Altorki N, Chung WJ, et al. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 1999;274:10911-5.
8. Csiki I, Yanagisawa K, Haruki N, et al. Thioredoxin- 1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1α in non-small cell lung cancer. Cancer Res 2006;66:143-50.
9. Mao JT, Cui X, Reckamp K, et al. Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clin Lung Cancer 2005;7:30-9.
10. Heuze-Vourc'h N, Zhu L, Krysan K, et al. Abnormal interleukin 10Rα expression contributes to the maintenance of elevated cyclooxygenase-2 in nonsmall cell lung cancer cells. Cancer Res 2003;63: 766-70.
11. Cui X, Zhang L, Luo J, et al. Unphosphorylated STAT6 contributes to constitutive cyclooxygenase- 2 expression in human non-small cell lung cancer. Oncogene 2007;26:4253-60.
12. Subbaramaiah K, Marmo TP, Dixon DA, et al. Regulation of cyclooxgenase-2 mRNAstabili ty by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR. J Biol Chem 2003;278: 37637-47.
13. Krysan K, Merchant FH, Zhu L, et al. COX-2- dependent stabilization of survivin in non-small cell lung cancer. FASEB J 2004;18:206-8.
14. Pold M, Krysan K, Pold A, et al. Cyclooxygenase- 2 modulates the insulin-like growth factor axis in non-small-cell lung cancer. Cancer Res 2004;64: 6549-55.
15. Sharma S, Stolina M, Yang SC, et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res 2003;9:961-8.
16. Pold M, Zhu LX, Sharma S, et al. Cyclooxygenase- 2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer. Cancer Res 2004;64:1853-60.
17. Dohadwala M, Batra RK, Luo J, et al. Autocrine/ paracrine prostaglandin E2 production by nonsmall cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase- 2-dependent invasion. J Biol Chem 2002;277: 50828-33.
18. Dohadwala M, Yang SC, Luo J, et al. Cyclooxygenase- 2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res 2006;66:5338-45.
19. Mao JT, Fishbein MC, Adams B, et al. Celecoxib decreases Ki-67 proliferative index in active smokers. Clin Cancer Res 2006;12:314-20.
20. Kim E, Hong W, Lee J, et al. Arandomized doubleblind study of the biological effects of celecoxib as a chemoprevention agent in current and former smokers. J Clin Oncol 2008. May 20 suppl.
21. Keith RL, Miller YE, Hoshikawa Y, et al. Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res 2002;62:734-40.
22. Mao JT, Tsu IH, Dubinett SM, et al. Modulation of pulmonary leukotriene B4 production by cyclooxygenase- 2 inhibitors and lipopolysaccharide. Clin Cancer Res 2004;10:6872-8.
23. Cha Y, DuBois R. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 2007;58:239-52.
24. Breyer R, Kennedy C, Zhang Y, et al. Structurefunction analyses of eicosanoid receptors. Physiologic and therapeutic implications. Ann N Y Acad Sci 2000;905:221-31.
25. Yang L, Huang Y, Porta R, et al. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res 2006;66:9665-72.
26. 2 receptor subtype EP4 in lung carcinoma cells through multiple signaling pathways: the role of AP-2. J Biol Chem 2007;282:7961-72.
27. 2 activates mitogen-activated protein kinase/ Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res 2005;65:6275-81.
28. Ding Y, Tong M, Liu S, et al. NAD+-linked 15- hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 2005;26:65-72.
29. Wolf I, O'Kelly J, Rubinek T, et al. 15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 2006;66:7818-23.
30. Cho H, Tai HH. Inhibition of NAD+-dependent 15- hydroxyprostaglandin dehydrogenase (15-PGDH) by cyclooxygenase inhibitors and chemopreventive agents. Prostaglandins Leukot Essent Fatty Acids 2002;67:461-5.
31. 2 catabolism in regulation of peroxisome proliferator-activated receptor γ activation. J Biol Chem 2007;282: 18162-72.
32. Hughes D, Otani T, Yang P, et al. NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer. Cancer Prev Res 2008.
33. Huang G, Eisenberg R, Yan M, et al. 15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3β and a tumor suppressor in lung cancer. Cancer Res 2008;68:5040-8.
34. Yang L, Amann JM, Kikuchi T, et al. Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer. Cancer Res 2007;67: 5587-93.
35. Heinrich E, Dohadwala M, Charuworn B, et al. Inflammation-dependent regulation of epithelialmesenchymal transition in non-small cell lung cancer: the role of interleukin-1β. Proc A m Assoc Cancer Res 2008;5366.
36. Jakobsson PJ, Thoren S, Morgenstern R, et al. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A 1999;96:7220-5.
37. Uppal S, Diggle CP, Carr IM, et al. Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. Nat Genet 2008;40:789-93.
38. Piper PJ, Vane JR, Wyllie JH. Inactivation of prostaglandins by the lungs. Nature 1970;225:600-4.
39. Coggins KG, Coffman TM, Koller BH. The Hippocratic finger points the blame at PGE2. Nat Genet 2008;40:691-2.
40. Lavin-Martinez M. Exploring the cause of the most ancient clinical sign of medicine: finger clubbing. Semin Arthritis Rheum 2007;36:380-5.
41. Tai HH, Tong M, Ding Y. 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer. Prostaglandins Other Lipid Mediat 2007;83:203-8.
42. Tong M, Ding Y, Tai HH. Histone deacetylase inhibitors and transforming growth factor-β induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells. Biochem Pharmacol 2006;72:701-9.
43. 2 in nonsmall- cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol Pharmacol 2007;71:1715-20.
44. Holla V, Backlund M, Yang P, et al. Regulation of prostaglandin transporters in colorectal neoplasia. Cancer Prev Res 2008;1:93-9.